GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
250 articles on this topic
-
Semaglutide Pill vs Injection: What Exists
There is a semaglutide pill. There is no tirzepatide pill, and there is unlikely to be one. Understanding why comes down to what happens to a 39-amino-acid peptide in your stomach.
-
Microdosing Tirzepatide: What It Means
Six-month observational data compare 2.5 mg with 5 mg, but smaller, split or extended-interval doses lack randomized trial evidence, and the term has no clinical definition. That does not make it unreasonable — but it does change what you can honestly expect from it.
-
Semaglutide Dosage: The 17-Week Ladder
The Wegovy injection schedule for weight management climbs through five doses over sixteen weeks before reaching 2.4 mg. That deliberate pace is the single best-supported way to make the first months tolerable.
-
Tirzepatide Dosage and the Titration Ladder
Every tirzepatide dose ladder starts at 2.5 mg and climbs in 2.5 mg steps no sooner than every four weeks. Understanding why that interval exists tells you most of what you need to know about your own schedule.
-
Tirzepatide Side Effects, From Common to Rare
Gastrointestinal effects are the ones almost everyone asks about — and across the tirzepatide dose range they affect 39% to 49% of people, concentrated in the weeks when the dose is going up.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
-
Tirzepatide vs Semaglutide: The Head-to-Head Data
In the SURMOUNT-5 trial, adults with obesity but without diabetes averaged 20.2% body-weight loss on tirzepatide and 13.7% on semaglutide over 72 weeks.
-
Tirzepatide Clinical Trials: What the Data Show
Two phase 3 programmes, a cardiovascular outcome trial that reported in December 2025, and more than 18,000 participants — here is what the published evidence actually shows, dose by dose.
-
Semaglutide Weight Loss Results: 14.9% in 68 Weeks
Adults with obesity in the 68-week STEP 1 trial lost an average of 14.9% of their body weight on weekly semaglutide, while the placebo group averaged 2.4%.
Page 13 of 13 · 250 articles